Martyn Darby
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$15.5MFederal grants as PI27 awards
0Patents grantedNone matched
22Papers790 citations
Federal awards and patents by year
AwardsPatents
27 awards · $15.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 21, 2024 | NIH | SBIR Phase II A novel peptide assay for hepcidin clinical monitoring | $591K | AFFINERGY, LLC |
| Aug 1, 2023 | NIH | SBIR Phase II A novel peptide assay for hepcidin clinical monitoring | $614K | AFFINERGY, LLC |
| May 11, 2022 | NIH | SBIR Phase II Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | $683K | AFFINERGY, LLC |
| Feb 28, 2022 | NIH | SBIR Phase II A Rapid Point of Care Test for APOL1 Renal Risk Alleles | $741K | AFFINERGY, LLC |
| Jun 30, 2021 | NIH | SBIR Phase II A Rapid Point of Care Test for APOL1 Renal Risk Alleles | $685K | AFFINERGY, LLC |
| Jun 24, 2021 | NIH | SBIR Phase II Novel assay to monitor Tacrolimus levels at the point of care | $735K | AFFINERGY, LLC |
| May 3, 2021 | NIH | SBIR Phase II Development of a novel clinical assay for measuring everolimus levels | $649K | AFFINERGY, LLC |
| Apr 27, 2021 | NIH | SBIR Phase II Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | $679K | AFFINERGY, LLC |
| Jun 26, 2020 | NIH | SBIR Phase II Novel assay to monitor Tacrolimus levels at the point of care | $734K | AFFINERGY, LLC |
| Jun 20, 2020 | NIH | SBIR Phase I Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis | $300K | AFFINERGY, LLC |
| May 12, 2020 | NIH | SBIR Phase II Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | $590K | AFFINERGY, LLC |
| Apr 21, 2020 | NIH | SBIR Phase II Development of a novel clinical assay for measuring everolimus levels | $718K | AFFINERGY, LLC |
| Jul 29, 2019 | NIH | SBIR Phase II Novel assay to monitor Tacrolimus levels at the point of care | $759K | AFFINERGY, LLC |
| May 20, 2019 | NIH | SBIR Phase II Development of a novel clinical assay for measuring everolimus levels | $744K | AFFINERGY, LLC |
| Apr 29, 2019 | NIH | SBIR Phase II Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | $283K | AFFINERGY, LLC |
| Feb 28, 2019 | NIH | SBIR Phase I Development of a multiplex peptide array to identify patients with an autoantibody signature for chronic pain | $320K | AFFINERGY, LLC |
| Jul 18, 2018 | NIH | SBIR Phase II Stem cell-binding peptides for rapid fixation of total hip replacements | $746K | AFFINERGY, LLC |
| Jun 15, 2018 | NIH | SBIR Phase II Novel assay to monitor Tacrolimus levels at the point of care | $300K | AFFINERGY, LLC |
| Sep 20, 2017 | NIH | SBIR Phase I Novel PhageLock assay to measure hepcidin for clinical monitoring | $333K | AFFINERGY, LLC |
| Aug 21, 2017 | NIH | SBIR Phase II Phage-based assay to measure daptomycin concentration in biological fluids | $671K | AFFINERGY, LLC |
| Aug 3, 2017 | NIH | SBIR Phase II Stem cell-binding peptides for rapid fixation of total hip replacements | $1.5M | AFFINERGY, LLC |
| Mar 9, 2017 | NIH | SBIR Phase I Peptide based tool for the rapid isolation of quiescent monocytes from peripheral blood | $309K | AFFINERGY, LLC |
| Mar 9, 2017 | NIH | SBIR Phase I Peptide-based tool for the rapid isolation of quiescent monocytes from peripheral blood | $309K | AFFINERGY, LLC |
| Sep 16, 2016 | NIH | SBIR Phase I Peptide-based slides for improving the diagnostic quality of sputum specimens | $300K | AFFINERGY, LLC |
| Aug 9, 2016 | NIH | SBIR Phase II Phage-based assay to measure daptomycin concentration in biological fluids | $669K | AFFINERGY, LLC |
| Apr 1, 2015 | NIH | SBIR Phase I Beta-2 Microglobulin Depletion Columns for Amyloidosis Prevention and Treatment | $294K | AFFINERGY, LLC |
| Jan 23, 2015 | NIH | SBIR Phase I Phage-based assay to measure daptomycin concentration in biological fluids | $257K | AFFINERGY, LLC |
1 patents as inventor
- US AFFINERGY, LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#22
Awards as PI#10
Patents#505
Companies
- AFFINERGY, LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.